Compare iShares Global Clean Energy ETF (ICLN) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares Global Clean Energy ETF trades at $17.26 (market cap $2.27B), while Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M). The key difference: iShares Global Clean Energy ETF is far larger — about 20.2× Inovio Pharmaceuticals Inc's market cap, and iShares Global Clean Energy ETF is more actively traded (6,845,064 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| ICLN | INO | |
|---|---|---|
Market Cap | $2.27B | $112.19M |
Volume | 6,845,064 | 3,201,278 |
52-Week High | $23.75 | $2.65 |
52-Week Low | $15.78 | $0.66 |
Typical Hold Time | 87 Days | 43 Days |
Sector | — | Health |
Enterprise Value | — | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.25, down 0.35% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 52.71 and 38.71. Recent news highlights ICLN's higher volatility and expense ratio compared to traditional energy ETFs, though geopolitical tensions and data center demand provide tailwinds for clean energy adoption.
The outlook remains challenged by competitive pressure from higher-yielding energy alternatives and significant historical drawdowns. However, global renewable energy acceleration and China's EV targets offer long-term growth potential. Key risks include fee structure disadvantages and sector volatility.
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
